Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of aerosolized MDT-637 in healthy adults challenged with RSV-A
2012-001107-20Phase 2Completed
- Sponsor
- MicroDose Therapeutx
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing MDT-637 with Placebo (2 arms). Primary endpoint: Antiviral effect measured by reduction in viral load AUC. Started Jul 2013; status: completed.
02
Drugs
MDT-637
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2012-001107-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001107-20.